Cigna To Exit Obamacare In 2027, Affecting Coverage For 369,000

Why It Matters

The exit shrinks the ACA marketplace, leaving hundreds of thousands of consumers to find new coverage and increasing pressure on remaining insurers and policymakers to address affordability gaps.

Key Takeaways

• Cigna will leave ACA individual market by 2027, affecting 369,000 members.
• Q1 enrollment fell 17% to 369,000, down from 446,000 last year.
• Industry enrollment dropping as enhanced subsidies expire, hitting Centene, UnitedHealth.
• Cigna will concentrate on commercial, employer and pharmacy‑benefit services.
• Net income rose to $1.7 billion, revenues $68.5 billion, driven by Evernorth growth.

Pulse Analysis

Cigna's decision to withdraw from the ACA individual exchange underscores a broader contraction in the marketplace as federal subsidies wane. The company reported a 17% drop in enrollment, reflecting consumer sensitivity to premium spikes once enhanced tax credits disappear. This trend mirrors industry peers—Centene lost two million members and UnitedHealth’s enrollment slipped by 300,000—signaling that the subsidy phase‑out is reshaping demand for low‑cost, high‑deductible plans.

For the 369,000 members Cigna will leave behind, the transition could mean higher out‑of‑pocket costs or the need to secure employer‑based coverage. Insurers that remain in the exchange may see an influx of higher‑risk enrollees, potentially driving premium adjustments and prompting state regulators to scrutinize market stability. Policymakers face renewed pressure to restore or redesign subsidy mechanisms to prevent a coverage gap for middle‑ and low‑income households.

Strategically, Cigna is redirecting capital toward its more profitable commercial and pharmacy‑benefit segments, highlighted by Evernorth’s contribution to a 5% revenue lift and a $1.7 billion net profit. By shedding a low‑margin ACA portfolio, the firm aims to boost return on equity and fund growth in employer‑sponsored plans and specialty pharmacy services. The move illustrates how large health insurers are recalibrating portfolios in response to shifting regulatory landscapes and consumer affordability challenges.